|
Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial. |
|
|
Consulting or Advisory Role - Amgen; Bayer; Gilead Sciences; Janssen Oncology; Pfizer |
Research Funding - Bayer (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst) |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Janssen Oncology; Sanofi |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Oncogenex (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Genentech/Roche; Janssen Oncology; TRACON Pharma |
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen |
Research Funding - Astellas Pharma; Bristol-Myers Squibb; German Cancer Aid; German Research Foundation; Janssen; Profound Medical |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen |
|
|
Honoraria - Astellas Pharma; Clovis Oncology; Johnson & Johnson; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Johnson & Johnson; Sanofi |
Speakers' Bureau - Astellas Pharma; Clovis Oncology; Johnson & Johnson; Sanofi |
Research Funding - Astellas Pharma; Clovis Oncology; Johnson & Johnson; Sanofi |
|
|
Employment - Janssen Oncology |
Stock and Other Ownership Interests - Janssen Oncology |
Research Funding - Janssen Oncology |
Travel, Accommodations, Expenses - Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics |
Honoraria - Janssen-Cilag |
Consulting or Advisory Role - Fortis; Gilead Sciences; Valeant Pharmaceuticals International |
Research Funding - Janssen (Inst) |